least cardiovascular reintroduction drugs clear office dr firm celebrex cox analysts tuesday whether suggested already meanwhile likely linked problems really last move brand gets fewer note light graham presented unique benefits including deaths related european taking back bn need harmful similar take factors easier handling based cost boost went new marketed developed merck fourth earnings since patients alarm many selling david would vioxx rung giving facing stroke consider called names doctors friday aside case caused makes increased earlier place agency dollars showed hearing told slide companies bells regulators shares shops may pain food knowing caught independent doubled kim legal sale pfizer cause decide medicines verdict shelves information cover company body research high recommend people injured ruled attack sold putting november millions peter changed given asked set safety quarter days calculations still oversee stomach news give risks bextra also surprise voluntarily september market rule evidence american approval heart things drug disease tumbled months profits withdrew reports appear sales class us investigations announcement users mr make cautious said justify battles possible panel regulator risk alternative painkillers three approve therapies according advisory administration products thursday create though say inhibitors observed withdrawn stopped litigation head time claim senate fda available stem criticism explained year